Cannabix Technologies Granted Cannabis Drug Detection Device Canadian Patent, Delivers THCBA to US Clinic
UF startup Cannabix Technologies Inc., developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, announces that the Canadian Intellectual Property Office (CIPO) has granted patent No. 2887841 entitled, “Cannabis Drug Detection Device”. The Company has been pursuing this original patent application since its filing on April 16, 2015. Cannabix Technologies is at the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (THC) – the psychoactive component of marijuana that causes impairment.
“Similar to our USPTO patent, the intellectual property protection this THC detection patent covers, gives Cannabix a broad foundation to build upon in view of the formidable insights and technical advancements made in the field of molecular gas analysis at atmospheric pressure that we have developed since this patent was initially filed in 2015. This patent is a useful plank in our IP protection strategy,” said Dr. Raj Attariwala, chief scientific officer at Cannabix Technologies.
Learn more about Cannabix Technologies Granted Cannabis Drug Detection Device Canadian Patent, Delivers THCBA to US Clinic.